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The wide spectrum of morbidity associated with steroids
has generated great enthusiasm in considering how they
might be eliminated from immunosuppression regimens.
Historically attempts to slowly wean steroids have yielded
high rates of acute rejection (1,2), raising concerns for a
potential increased risk of graft loss. Subsequent studies
have focused on early steroid withdrawal or steroid avoid-
ance. While many of the reports have been single center
and nonrandomized, these studies have often been of large
size and suggest that steroid minimization may be safe in
the short term and in the correct setting (3–6). While these
reports are encouraging, the issue of early steroid avoid-
ance has not been tested with the same rigor the FDA
would evaluate a new agent or new immunosuppressive
regimen.
In the current issue of AJT, Vincenti and his collaborators
from the ‘FREEDOM’ Study take an important step in this
direction. This group reports a well designed prospective
randomized trial to evaluate whether total steroid avoid-
ance or early steroid withdrawal has a more favorable risk-
benefit ratio compared to a standard maintenance steroid
regimen, in recipients receiving basiliximab induction and
maintenance cyclosporine in the microemulsion formula-
tion and mycophenolate sodium (7). The study is relatively
unique in that it allows evaluation of both steroid avoidance
and early steroid withdrawal across a common protocol.
Other strengths of the trial include a thorough evaluation
of comorbidities associated with steroid therapy.
Both experimental arms of steroid avoidance and early
withdrawal failed to meet the primary noninferiority end-
point for renal function compared to steroid maintenance.
This study was designed with a noninferiority primary
endpoint powered to demonstrate noninferiority of ei-
ther early steroid withdrawal or avoidance regarding cal-
culated glomerular filtration rate (GFR) at 12 months, with
a fairly wide noninferiority margin set at a difference of
7 mL/min/1.73 m2 at 1 year posttransplant. Despite of
this rather large margin to define inferior renal function
the noninferiority condition was not met by either exper-
imental arm in primary the intent-to-treat analysis. Only
in a reduced sample of patients described as ‘observed
case analysis’, the noninferiority hypothesis was met but
after excluding 25% of patients in each arm. It is also
worthy to note that the steroid-free group had more living
donors, which would tend to bias this group toward better
outcomes.
In strictest terms according to its own design, the trial did
not prove efficacy and safety of either investigational arm
for the primary study endpoint. Stated another way, the
trial did not prove that steroid avoidance or steroid with-
drawal were not inferior to maintenance steroid therapy.
Consequently it is not possible to draw a sound conclu-
sion regarding the relative risk-benefit ratio of either steroid
withdrawal or steroid avoidance in this study.
An advantage of utilizing a noninferiority design is that it of-
ten allows for a smaller sample size in terms of the primary
endpoint (8). However, this also means that subanalyses
and secondary endpoints are potentially under-powered.
In addition population subanalyses can introduce signifi-
cant selection biases by altering the makeup of the original
study population by typically looking at lower risk patients.
The potential impact of sub sampling on sample size like
in the ‘per protocol analysis’ in the FREEDOM trial is high-
lighted by the observation that at 12 months, only 59%
of the patients randomized to the steroid avoidance arm
and 71% of the patients in the steroid withdrawal group
were free of steroids. Furthermore, 12% of the patients
in the steroid maintenance arm had actually had steroids
withdrawn, at odds with the protocol. Renal function as a
primary endpoint has a potential bias already built in as it
can be measured only in patients with a functioning graft.
Unless graft losses are counted as a low GFR value in the
analysis, differential graft loss between the analysis groups
can introduce a significant bias.
The potential loss of power by subanalyses is also nicely
illustrated in the ‘FREEDOM’ trial looking at the acute
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rejection data. In the intent-to-treat analysis, the incidence
of biopsy-proven acute rejection was statistically higher in
both the steroid avoidance (31.5%) and the steroid with-
drawal (26.1%) arms compared to maintenance steroid
group (14.7%). When the investigators evaluated sub-
groups, including only recipients without delayed graft
function or major protocol deviations, many of the differ-
ences became less apparent. In fact, the study was proba-
bly not powered to detect differences in the smaller sam-
ple size associated with these analyses. These offprotocol
patients also affect the interpretation of other endpoints,
specifically those related to the benefits of freedom from
steroids.
Because the current trial was open label, it is possible
that investigators were more likely to biopsy the recipi-
ents not receiving maintenance steroids, potentially lead-
ing to a higher rate of detection of rejection. A double blind
study design would help address this bias. The only dou-
ble blind randomized trial of early steroid withdrawal to
date is the trial being conducted by the Astellas Steroid
Withdrawal Group. Woodle et al., in the recent update
of this trial reported that the steroid withdrawal group,
treated with induction therapy and maintenance tacrolimus
and mycophenolate mofetil has had more clinical acute re-
jection episodes and had a statistically significantly higher
incidence of chronic allograft nephropathy at 4 years com-
pared to the steroid maintenance group (9). It is impor-
tant to note that comparability between these two trials
and others is limited by the differences in induction and
maintenance immunosuppression employed. To date most
studies of early steroid withdrawal have been designed
based on the currently most widely used immunosuppres-
sive maintenance regimen of tacrolimus combined with
mycophenolate mofetil and variable induction therapy. The
results of the current trial by Vincenti et al. have to be inter-
preted within the setting of cyclosporin microemulsion and
mycophenolate sodium maintenance immunosuppression
with concurrent basiliximab induction.
Whether any potential decreases in toxicities are worth
an increased risk of acute rejection and worse renal func-
tion, would have to be addressed by studies with longer
follow-up and hard endpoints like graft and patient survival.
Further studies based on rigorous study design and anal-
yses are needed to define the risk-benefit ratio of steroid
avoidance strategies and assess the clinical safety of this
rapidly proliferating strategy.
The study by Vincenti et al. is a considerable step forward in
the understanding of the risks and benefits associated with
steroid avoidance. It helps highlight that in addition to the
widely advertised benefits of steroid avoidance strategies,
there are potential risks of more acute rejection and worse
renal function.
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